Microbiota and metabolic diseases - PubMed (original) (raw)
Review
. 2018 Sep;61(3):357-371.
doi: 10.1007/s12020-018-1605-5. Epub 2018 May 2.
Affiliations
- PMID: 29721802
- DOI: 10.1007/s12020-018-1605-5
Review
Microbiota and metabolic diseases
Alessia Pascale et al. Endocrine. 2018 Sep.
Abstract
The microbiota is a complex ecosystem of microorganisms consisting of bacteria, viruses, protozoa, and fungi, living in different districts of the human body, such as the gastro-enteric tube, skin, mouth, respiratory system, and the vagina. Over 70% of the microbiota lives in the gastrointestinal tract in a mutually beneficial relationship with its host. The microbiota plays a major role in many metabolic functions, including modulation of glucose and lipid homeostasis, regulation of satiety, production of energy and vitamins. It exerts a role in the regulation of several biochemical and physiological mechanisms through the production of metabolites and substances. In addition, the microbiota has important anti-carcinogenetic and anti-inflammatory actions. There is growing evidence that any modification in the microbiota composition can lead to several diseases, including metabolic diseases, such as obesity and diabetes, and cardiovascular diseases. This is because alterations in the microbiota composition can cause insulin resistance, inflammation, vascular, and metabolic disorders. The causes of the microbiota alterations and the mechanisms by which microbiota modifications can act on the development of metabolic and cardiovascular diseases have been reported. Current and future preventive and therapeutic strategies to prevent these diseases by an adequate modulation of the microbiota have been also discussed.
Keywords: Cardiovascular disease; Diabetes; Metabolic syndrome; Microbiome; Microbiota; Obesity.
Similar articles
- Emerging role of intestinal microbiota and microbial metabolites in metabolic control.
Herrema H, IJzerman RG, Nieuwdorp M. Herrema H, et al. Diabetologia. 2017 Apr;60(4):613-617. doi: 10.1007/s00125-016-4192-0. Epub 2016 Dec 24. Diabetologia. 2017. PMID: 28013341 - A Role for Timp3 in Microbiota-Driven Hepatic Steatosis and Metabolic Dysfunction.
Mavilio M, Marchetti V, Fabrizi M, Stöhr R, Marino A, Casagrande V, Fiorentino L, Cardellini M, Kappel B, Monteleone I, Garret C, Mauriello A, Monteleone G, Farcomeni A, Burcelin R, Menghini R, Federici M. Mavilio M, et al. Cell Rep. 2016 Jul 19;16(3):731-43. doi: 10.1016/j.celrep.2016.06.027. Epub 2016 Jun 30. Cell Rep. 2016. PMID: 27373162 - [Gut microbiota and immune crosstalk in metabolic disease].
Burcelin R. Burcelin R. Biol Aujourdhui. 2017;211(1):1-18. doi: 10.1051/jbio/2017008. Epub 2017 Jul 6. Biol Aujourdhui. 2017. PMID: 28682223 Review. French. - Gut microbiota in health and disease: an overview focused on metabolic inflammation.
Nagpal R, Kumar M, Yadav AK, Hemalatha R, Yadav H, Marotta F, Yamashiro Y. Nagpal R, et al. Benef Microbes. 2016;7(2):181-94. doi: 10.3920/bm2015.0062. Epub 2015 Dec 8. Benef Microbes. 2016. PMID: 26645350 Review. - Role of the gut microbiota in type 2 diabetes and related diseases.
Yang G, Wei J, Liu P, Zhang Q, Tian Y, Hou G, Meng L, Xin Y, Jiang X. Yang G, et al. Metabolism. 2021 Apr;117:154712. doi: 10.1016/j.metabol.2021.154712. Epub 2021 Jan 23. Metabolism. 2021. PMID: 33497712 Review.
Cited by
- Engineering Probiotics for Diabetes Management: Advances, Challenges, and Future Directions in Translational Microbiology.
Zhang S, Ma J, Ma Y, Yi J, Wang B, Wang H, Yang Q, Zhang K, Yan X, Sun D, You J. Zhang S, et al. Int J Nanomedicine. 2024 Oct 28;19:10917-10940. doi: 10.2147/IJN.S492651. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39493275 Free PMC article. Review. - Bacterial and clinical metabolic signatures and their interactions in obese patients post-bariatric surgery.
Hu M, Xiang Q, Mei Z, Gong C, Pan D, Liu Y, Li Z. Hu M, et al. BMC Gastroenterol. 2024 Oct 12;24(1):363. doi: 10.1186/s12876-024-03450-1. BMC Gastroenterol. 2024. PMID: 39394090 Free PMC article. - LysoPE mediated by respiratory microorganism Aeromicrobium camelliae alleviates H9N2 challenge in mice.
Yan Q, Xing J, Zou R, Sun M, Zou B, Wang Y, Niu T, Yu T, Huang H, Yang W, Shi C, Yang G, Wang C. Yan Q, et al. Vet Res. 2024 Oct 11;55(1):136. doi: 10.1186/s13567-024-01391-x. Vet Res. 2024. PMID: 39390593 Free PMC article. - Modulation of gut microbiota by diet and probiotics: potential approaches to prevent gestational diabetes mellitus.
Cruz MC, Azinheiro S, Pereira SG. Cruz MC, et al. Gut Microbiome (Camb). 2023 Jun 13;4:e17. doi: 10.1017/gmb.2023.6. eCollection 2023. Gut Microbiome (Camb). 2023. PMID: 39295903 Free PMC article. Review. - Development of systemic and mucosal immune responses against gut microbiota in early life and implications for the onset of allergies.
Pirker AL, Vogl T. Pirker AL, et al. Front Allergy. 2024 Jul 17;5:1439303. doi: 10.3389/falgy.2024.1439303. eCollection 2024. Front Allergy. 2024. PMID: 39086886 Free PMC article. Review.
References
- Nature. 2008 Oct 23;455(7216):1109-13 - PubMed
- Gut. 2003 Oct;52(10):1442-7 - PubMed
- Nat Cell Biol. 2011 Sep 02;13(9):1016-23 - PubMed
- Endocrine. 2017 Nov;58(2):207-227 - PubMed
- Front Microbiol. 2016 Feb 17;7:185 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical